Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an effective class of glucose-lowering agents that exert their action by enhancing glucose-dependent insulin secretion, suppressing glucagon, and delaying gastric emptying, which contributes to increased satiety and weight reduction [11,12]; given these pleiotropic effects, GLP-1 RAs have been positioned not only as antidiabetic agents but also as potential therapeutic tools in the management of obesity and cardiometabolic risk [13,14,15]. The gene discussed is GLP1R; the disease is obesity disorder.